Treatment of essential hypertension in adults
TELMISARTAN AND HYDROCHLOROTHIAZIDE — ALEMBIC, approved 2023-09-12 (ANDA203010).
17,594 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.